Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. Issue 10 (30th April 2015)

• Record Type: Journal Article
• Authors: Cunningham‐Myrie, Colette; Abdulkadri, Abdullahi; Waugh, Andre; Bortolusso Ali, Susanna; King, Lesley‐Gaye; Knight‐Madden, Jennifer; Reid, Marvin
• Is Part Of: Pediatric blood & cancer. Volume 62:Issue 10(2015:Oct.)
• Page Start: 1862
• Page End: 1864
• Publication Date: 2015-04-30
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.25563
• Languages: English
• ISSNs: 1545-5009

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="pbc25563-sec-0001" sec-type="section"> <p>We undertook a cost effectiveness analysis (CEA) of hydroxyurea (HU) in preventing stroke recurrence and/or death. We followed 43 children with sickle cell disease from 2000 to 2009 after having a first clinical stroke, of whom 10 opted for HU therapy. HU use led to decreased stroke recurrence and death without significantly increasing the annual cost of care per patient (J$83, 250 vs. J$76, 901, <italic>P</italic> = 0.491). The incremental cost effectiveness ratio (ICER) for prevention of stroke recurrence amounted to J$169, 238 (US$1, 900), while that for death prevention equalled J$635, 843 (US$7, 140). HU may be recommended when safe and affordable transfusion therapy is not feasible. Pediatr Blood Cancer 2015;62:1862–1864. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract>